Report: 71% of promised postmarketing commitments aren't started

Share this article:
FDA's latest annual report says 71% (911) of pending postmarketing study commitments promised by drug sponsors at the time of approval have never been started. This is almost unchanged from the year before (2006) when 899 (71%) were pending. Last year's FDA Amendments Act gave the agency authority to order more postmarketing studies to address safety issues.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.